Erectile dysfunction drug could treat Alzheimer’s disease

Maybe being stupid is a good thing.

With more than 900,000 people diagnosed with Alzheimer’s disease each year in the United States, scientists are looking for new and better treatments. And it turns out some remedies might be right under our noses (and on our nightstands).

Yes: the beloved little blue pill, Viagra, has shown promise in sending blood to the right places – like the brain, thereby preventing dementia.

And now, new research shows that a related drug, long used in Korea to treat erectile dysfunction, could soon help fight Alzheimer’s disease in the United States.


A happy elderly couple dancing and laughing outdoors.
Medications used for erectile dysfunction may have another use: protecting the brain from cognitive decline. Lumos sp – stock.adobe.com

The drug, called AR1001, uses a lower dose of mirodenafil, an erectile dysfunction treatment used in Korea since 2007, to potentially treat Alzheimer’s disease.

A new clinical trial found that it slowed cognitive decline by 31%, but only in a certain population.

AR1001’s maker, AriBio, plans to seek FDA approval in 2027, meaning this new research could pave the way for the drug to hit the U.S. market in the next few years.

Mirodenafil, sildenafil… and Alzheimer’s

Mirodenafil, the active ingredient in the new drug, and sildenafil, the active ingredient in Viagra, belong to the same class of drugs: PDE5 inhibitors.

These work by controlling the breakdown of a chemical messenger called cGMP, keeping muscles relaxed and improving blood flow.

Normally, they are prescribed to direct blood to the penis. But now these drugs are being studied for their ability to improve blood flow in the brain and improve cognitive function.

Blood flow plays a key role in the development of Alzheimer’s disease. Reduced blood flow allows toxic amyloid plaques to build up and does not provide enough oxygen and nutrients to supply brain cells.


A shirtless man pouring blue pills from a bottle into his hand.
AR1001 is a once-daily pill. Other treatment options for progression of Alzheimer’s disease are IV infusions. Oleg – stock.adobe.com

What you need to know about the AR1001

Unlike sildenafil, mirodenafil is not currently approved by the FDA for the treatment of erectile dysfunction or any other use. But it has been approved in Korea for erectile dysfunction since 2007.

The latest research was part of its Phase 3 clinical trials to study its safety and effectiveness for treating Alzheimer’s disease. This is the final step before seeking FDA approval in the United States.

After one year, patients taking AR1001 who were not taking standard Alzheimer’s medications experienced 31% less clinical decline than those taking a placebo, the researchers found.

However, when researchers looked at all 1,535 participants, including those taking other Alzheimer’s medications, the difference between AR1001 and placebo was not statistically significant.

AR1001 users also generally performed better on tests measuring memory, cognition, and daily functioning, although not all results were statistically significant.

The researchers also found that AR1001 appeared to prevent the breakdown of a molecule that helps brain cells communicate, further evidence that the drug was having the desired effect.

Treating Alzheimer’s Disease

There is no cure for Alzheimer’s disease, but there are treatments for the symptoms and treatments that slow the progression of the disease.

There are currently only two drugs approved to slow the progression of the disease: Donanemab (Kisunla) and Lecanemab (Leqembi). Both are IV infusions and are designed for the early stage of Alzheimer’s disease.

AR1001 could potentially join these two drugs approved to slow the progression of Alzheimer’s disease, but comes in the form of a once-daily pill. It is also only being studied for early-stage Alzheimer’s disease.

“We began developing AR1001 with the goal of creating an oral treatment that could slow the progression of Alzheimer’s disease and be practical for patients…to use over the long term,” said Jai-Jun Choung, CEO of AriBio.

The latest results “support our hypothesis,” he added. “Our vision is to expand the treatment options available to patients and their families. »

Gn bussni

Logo